Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

27 Sep 2005 12:09

Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2005 Chairman's statementIn the six months ended 30 June 2005 the Company incurred a loss before andafter taxation of ‚£74,000 (2004: ‚£229,000).Because of the lack of cash in the Company, creditors have increased butcontinue to be supportive.The directors are continuing to keep overheads to a minimum, the expenses beingthose necessary to maintain the Company's listing on AIM.The board continues to seek an acquisition for the Company.Owing to a technicality, the Company no longer has any authority to issue anyof its share capital and will therefore be convening an extraordinary generalmeeting for this purpose.Nicolas GreenstoneChairman27 September 2005Azure Holdings plcProfit and Loss Accountfor the six months ended 30 June 2005 6 months 6 months Year ended ended 30 ended 30 31 December June 2004 2004 June 2005 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Turnover - - - Administrative expenses (74) (229) (345) Operating loss (74) (229) (345) Loss on ordinary activities before (74) (229) (345)taxation Tax on loss on ordinary activities - - - Loss on ordinary activities after (74) (229) (345)taxation Retained loss for the period (74) (229) (345) Loss per ordinary share (0.15p) (0.65p) (0.86p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains andlosses.Azure Holdings plcBalance Sheetas at 30 June 2005 30 June 2005 30 June 31 December 2004 2004 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Current assets Debtors 3 14 7 Cash at bank and in hand 1 10 14 4 24 21 Creditors: amounts falling due within one (147) (81) (90)year Net current liabilities (143) (57) (69) Total assets less current liabilities (143) (57) (69) Net liabilities (143) (57) (69) Capital and reserves Called up Share Capital 5,475 5,371 5,475 Share Premium 10,279 10,279 10,279 Profit and loss account (15,897) (15,707) (15,823) Equity shareholders deficit (143) (57) (69) Azure Holdings plcCash Flow Statementfor the six months ended 30 June 2005 6 months ended 6 months ended 30 June 2005 30 June 2004 (unaudited) (unaudited) ‚£'000 ‚£'000 Net cash outflow from operating (13) (214)activities Financing Issue of ordinary shares - 105 Decrease in cash (13) (109)Azure Holdings plcNotes to the Interim Results 1. The interim results are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The figures for the year ended 31 December 2004 have been extracted from the statutory accounts filed with the registrar of companies on which the auditors gave an unqualified report. 2. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2004. 3. The comparative figures for the unaudited interim results for the period ended 30 June 2004 are stated as announced on 29 September 2004. 4. Loss per share The earnings per share for the six months ended 30 June 2005 has beencalculated on the basis of the loss after taxation for the period of ‚£74,000(2004: ‚£229,000 ) and the weighted average number of shares in issue during theperiod of 48,317,569 (2004: 35,417,565). 5. The directors do not propose to pay a dividend for the period. 6. Copies of the interim results are available from the Company's registered office, One Great Cumberland Place, London, W1H 7AL. ENDAZURE HOLDINGS PLC
Date   Source Headline
11th Oct 20127:00 amRNSre: UK Distribution Agreement
20th Sep 20127:00 amRNSHalf Yearly Report
6th Sep 20127:00 amRNSVAL201 Update re: Breast Cancer Study
2nd Aug 20127:00 amRNSRe: GeneICE and Biomarkers Development Update
29th May 201211:07 amRNSResult of AGM
29th May 20127:00 amRNSUpdate re: Late Pre-clinical Study of VAL201
15th May 20127:00 amRNSNew US Patent Grant
27th Apr 20127:00 amRNSFinal Results
2nd Apr 201212:17 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSPlacing of GBP 900,000 and Director's Dealing
29th Mar 20127:00 amRNSRe Agreement
8th Mar 20127:00 amRNSPeer Review Findings Published re VAL201
14th Feb 20127:00 amRNSEstablishment of Scientific & Advisory Board
2nd Feb 20127:00 amRNSNew European Patent Grant
31st Jan 201210:14 amRNSTotal Voting Rights
5th Jan 20127:00 amRNSAcquisition
15th Dec 20117:00 amRNSNew Patent Grant for GeneICE & VAL101 Update
9th Dec 20114:23 pmRNSRe Volition - Allotment of Shares
24th Nov 20117:00 amRNSHolding(s) in Company
3rd Nov 20117:00 amRNSNew Patent Filing
7th Oct 20118:00 amRNSVolition Update
27th Sep 20117:00 amRNSVolition Update
22nd Sep 20117:00 amRNSHalf Yearly Report
8th Sep 20117:00 amRNSDistribution Agreement
18th Aug 20117:00 amRNSAcquisition of Finnish Non-Trading Company
28th Jul 20117:00 amRNSVAL201 Update
19th Jul 20113:59 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSDirector/PDMR Shareholding
11th Jul 20117:00 amRNSGrant of Options
23rd Jun 201110:55 amRNSResult of AGM
23rd Jun 20117:00 amRNSAGM Statement
21st Jun 20117:00 amRNSGeneICE Update
10th Jun 20117:00 amRNSVolition - update
2nd Jun 20117:00 amRNSDirectorate Change
31st May 20111:30 pmRNSPublication of Report & Accounts and Notice of AGM
31st May 20117:00 amRNSTotal Voting Rights
31st May 20117:00 amRNSFinal Results
26th May 20112:56 pmRNSHolding(s) in Company
20th May 20117:00 amRNSWebsite update
14th Apr 20117:00 amRNSAgreements with Imperial College & Oxford Uni
9th Mar 20112:54 pmRNSHolding(s) in Company
9th Mar 201111:15 amRNSHolding(s) in Company
7th Mar 201110:56 amRNSResult of EGM
7th Mar 20117:00 amRNSStatement re General Meeting
25th Feb 20112:09 pmRNSWebsite Update
18th Feb 20112:54 pmRNSPublication of Circular and Notice of GM
16th Feb 20117:19 amRNSIssue of Equity
14th Feb 20117:00 amRNSUpdate
1st Feb 201111:38 amRNSTotal Voting Rights
31st Jan 20117:00 amRNSFurther re Sale of Belgian Subsidiary, ValiBIO SA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.